7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Radicular Cyst D011842 2 associated lipids
Gingival Recession D005889 2 associated lipids
Carcinoma, Medullary D018276 2 associated lipids
Dengue D003715 2 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Tooth Migration D014085 2 associated lipids
Musculoskeletal Diseases D009140 2 associated lipids
Hip Fractures D006620 2 associated lipids
No-Reflow Phenomenon D054318 2 associated lipids
Ossification, Heterotopic D009999 2 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Mackie PS et al. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. 2001 Br. J. Cancer pmid:11286476
Hofbauer LC et al. Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis. 2001 J. Rheumatol. pmid:11327234
Hofbauer LC and Heufelder AE The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. 2001 Arthritis Rheum. pmid:11229454
Leach RJ et al. The genetics of Paget's disease of the bone. 2001 J. Clin. Endocrinol. Metab. pmid:11231972
Luger NM et al. Osteoprotegerin diminishes advanced bone cancer pain. 2001 Cancer Res. pmid:11358823
Haynes DR et al. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. 2001 Rheumatology (Oxford) pmid:11426018
Szulc P et al. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. 2001 J. Clin. Endocrinol. Metab. pmid:11443182
Sakiyama H et al. Establishment and characterization of macrophage-like cell lines expressing osteoclast-specific markers. 2001 J. Bone Miner. Metab. pmid:11448014
Choi Y et al. Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. 2001 Eur. J. Immunol. pmid:11449372
Kanzaki H et al. Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. 2001 J. Dent. Res. pmid:11379890
Hein GE [Pathophysiology of bone loss in rheumatic diseases--do bone markers help in monitoring?]. 2001 Z Rheumatol pmid:11383046
Morony S et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. 2001 Cancer Res. pmid:11389072
Kim KJ et al. Osteoprotegerin inhibits in vitro mouse osteoclast formation induced by joint fluid from failed total hip arthroplasty. 2001 J. Biomed. Mater. Res. pmid:11410897
Abu-Amer Y IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. 2001 J. Clin. Invest. pmid:11390419
Kon T et al. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. 2001 J. Bone Miner. Res. pmid:11393777
Fazzalari NL et al. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. 2001 J. Bone Miner. Res. pmid:11393778
Bekker PJ et al. The effect of a single dose of osteoprotegerin in postmenopausal women. 2001 J. Bone Miner. Res. pmid:11204435
Kikuchi T et al. Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. 2001 J. Immunol. pmid:11207318
O'Brien EA et al. Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. 2001 Bone pmid:11182380
Thirunavukkarasu K et al. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. 2001 J. Biol. Chem. pmid:11451955
Yun TJ et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. 2001 J. Immunol. pmid:11160187
Stejskal D et al. Osteoprotegerin, RANK, RANKL. 2001 Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub pmid:12426773
Stejskal D et al. Osteoprotegerin and bone density. 2001 Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub pmid:12426776
Takemura M et al. Relationship between osteoprotegerin/osteoclastogenesis inhibitory factor concentration in synovial fluid and disease severity in individuals with osteoarthritis of the knee. 2001 Metab. Clin. Exp. pmid:11172466
Gravallese EM et al. The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. 2001 Arthritis Res. pmid:11178122
Makiishi-Shimobayashi C et al. Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. 2001 Biochem. Biophys. Res. Commun. pmid:11181055
Lories RJ and Luyten FP Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. 2001 Clin. Rheumatol. pmid:11254237
Wan M et al. Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression. 2001 J. Biol. Chem. pmid:11139569
Lean JM et al. FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. 2001 Blood pmid:11675341
Fiumara P et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. 2001 Blood pmid:11675352
Satoh K et al. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. 2001 Pancreas pmid:11590320
Yano K et al. Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancy. 2001 Biochem. Biophys. Res. Commun. pmid:11594776
Brown JM et al. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. 2001 Clin. Cancer Res. pmid:11595685
Price PA et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. 2001 Arterioscler. Thromb. Vasc. Biol. pmid:11597934
Nemec K and Schubert-Zsilavecz M [Future therapies for metabolic bone diseases. New concepts and targets]. 2001 Pharm Unserer Zeit pmid:11715689
Kuntz KA et al. An immunohistochemical study of osteoprotegerin in the human dental pulp. 2001 J Endod pmid:11716077
Hofbauer LC and Schoppet M Serum measurement of osteoprotegerin--clinical relevance and potential applications. 2001 Eur. J. Endocrinol. pmid:11720890
Ueland T et al. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. 2001 Eur. J. Endocrinol. pmid:11720891
Chikazu D et al. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. 2001 J. Bone Miner. Res. pmid:11697804
Khosla S Minireview: the OPG/RANKL/RANK system. 2001 Endocrinology pmid:11713196
Seidel C et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. 2001 Blood pmid:11568016
Fukagawa M et al. Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases. 2001 Am. J. Kidney Dis. pmid:11576943
Sato T et al. Osteoprotegerin levels before and after renal transplantation. 2001 Am. J. Kidney Dis. pmid:11576949
Feuerherm AJ et al. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. 2001 Scand. J. Rheumatol. pmid:11578019
Sakai E et al. Characterization of phagosomal subpopulations along endocytic routes in osteoclasts and macrophages. 2001 J. Biochem. pmid:11726283
Burguera B et al. Leptin reduces ovariectomy-induced bone loss in rats. 2001 Endocrinology pmid:11459801
Yamagishi T et al. Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. 2001 Endocrinology pmid:11459812
Ma YL et al. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. 2001 Endocrinology pmid:11517184
Bateman TA et al. Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. 2001 J. Orthop. Res. pmid:11518255
Myoung H et al. Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats. 2001 J. Periodont. Res. pmid:11519698
Haynes DR et al. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. 2001 J Bone Joint Surg Br pmid:11521937
Hofbauer LC and Schoppet M Osteoprotegerin: a link between osteoporosis and arterial calcification? 2001 Lancet pmid:11498208
Sakai A et al. 1alpha-Hydroxyvitamin D3 suppresses trabecular bone resorption by inhibiting osteoclastogenic potential in bone marrow cells after ovariectomy in mice. 2001 J. Bone Miner. Metab. pmid:11498729
Ikeda T et al. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. 2001 J. Bone Miner. Res. pmid:11499864
Thomas GP et al. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. 2001 J. Endocrinol. pmid:11479141
Allan GF et al. Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification. 2001 Steroids pmid:11546554
Feige U Osteoprotegerin. 2001 Ann. Rheum. Dis. pmid:11890662
Chung H et al. Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. 2001 J. Korean Med. Sci. pmid:11748360
Komuro H et al. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. 2001 Arthritis Rheum. pmid:11762937
Lindberg MK et al. Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. 2001 J. Endocrinol. pmid:11739008
Giuliani N et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. 2001 Blood pmid:11739153
Croucher PI et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. 2001 Blood pmid:11739154
Dhore CR et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. 2001 Arterioscler. Thromb. Vasc. Biol. pmid:11742876
Ramalho AC et al. Effect of oestradiol on cytokine production in immortalized human marrow stromal cell lines. 2001 Cytokine pmid:11792122
Yano K et al. Synovial cells from a patient with rheumatoid arthritis produce osteoclastogenesis inhibitory factor/osteoprotegerin: reciprocal regulation of the production by inflammatory cytokines and basic fibroblast growth factor. 2001 J. Bone Miner. Metab. pmid:11685652
Kawahara N et al. Two novel cucurbitacins, neocucurbitacins A and B, from the Brazilian folk medicine "Buchinha" (Luffa operculata) and their effect on PEBP2alphaA and OCIF gene expression in a human osteoblast-like Saos-2 cell line. 2001 Chem. Pharm. Bull. pmid:11605678
Boissy P et al. RANKL induces formation of avian osteoclasts from macrophages but not from macrophage polykaryons. 2001 Biochem. Biophys. Res. Commun. pmid:11606048
Wise GE et al. Effects of dexamethasone on tooth eruption in rats: differences in incisor and molar eruption. 2001 Clin Anat pmid:11301468
Atkins GJ et al. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. 2001 Bone pmid:11336917
Yan T et al. Regulation of osteoclastogenesis and RANK expression by TGF-beta1. 2001 Aug 1-9 J. Cell. Biochem. pmid:11573248
Rosa-Rañal M et al. [New paradigms in the regulation of bone metabolism]. 2001 Jul-Aug Rev. Invest. Clin. pmid:11599485
Geoffroy V et al. High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. 2002 Mol. Cell. Biol. pmid:12167715
Uemura H et al. Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers. 2002 J. Endocrinol. pmid:12176675
Ragab AA et al. Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells. 2002 Am. J. Physiol., Cell Physiol. pmid:12176725
Whyte MP et al. Osteoprotegerin deficiency and juvenile Paget's disease. 2002 N. Engl. J. Med. pmid:12124406
Inoue D and Matsumoto T [Recent advances in basic research of bone metabolism]. 2002 Nippon Rinsho pmid:11979916
Suzuki Y et al. [Bone destruction and bone loss in rheumatoid arthritis--mechanism, prevention and treatment]. 2002 Nippon Rinsho pmid:11979937
Inoue D [Recent advances in research of bone resorption]. 2002 Nippon Rinsho pmid:11979946
Udagawa N and Takahashi N [Possible role of receptor activator of NF-kappa B ligand(RANKL) in osteoclast differentiation and function]. 2002 Nippon Rinsho pmid:11979968
Tsuda E [Osteoclastogenesis inhibitory factor (OCIF)/OPG (a novel therapeutic candidate for the treatment of metabolic bone diseases)]. 2002 Nippon Rinsho pmid:11979969
Fu M et al. Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. 2002 Biochem. Biophys. Res. Commun. pmid:12056809
Kim YH et al. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. 2002 Exp. Mol. Med. pmid:12085990
Khosla S et al. Correlates of osteoprotegerin levels in women and men. 2002 Osteoporos Int pmid:12086350
Ueland T et al. Effects of 12 months of GH treatment on cortical and trabecular bone content of IGFs and OPG in adults with acquired GH deficiency: a double-blind, randomized, placebo-controlled study. 2002 J. Clin. Endocrinol. Metab. pmid:12050246
Sasaki N et al. Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. 2002 Bone pmid:12052453
Kudo O et al. Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. 2002 J. Pathol. pmid:12237882
Hofbauer LC et al. High bone density due to a mutation in LDL-receptor-related protein 5. 2002 N. Engl. J. Med. pmid:12240686
Okada Y et al. Cell-to-Cell adhesion via intercellular adhesion molecule-1 and leukocyte function-associated antigen-1 pathway is involved in 1alpha,25(OH)2D3, PTH and IL-1alpha-induced osteoclast differentiation and bone resorption. 2002 Endocr. J. pmid:12402981
Roodman GD Role of the bone marrow microenvironment in multiple myeloma. 2002 J. Bone Miner. Res. pmid:12412796
Ito S et al. Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. 2002 J. Biol. Chem. pmid:11733492
Buckley KA and Fraser WD Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. 2002 Ann. Clin. Biochem. pmid:12564836
Viereck V et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. 2002 Biochem. Biophys. Res. Commun. pmid:11855844
Romas E et al. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. 2002 Bone pmid:11856640
Viereck V et al. Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. 2002 J. Cell. Biochem. pmid:11835398
Wise GE et al. Inhibition of osteoclastogenesis by the secretion of osteoprotegerin in vitro by rat dental follicle cells and its implications for tooth eruption. 2002 Arch. Oral Biol. pmid:11839361
Faucheux C et al. Nuclear localization of type I parathyroid hormone/parathyroid hormone-related protein receptors in deer antler osteoclasts: evidence for parathyroid hormone-related protein and receptor activator of NF-kappaB-dependent effects on osteoclast formation in regenerating mammalian bone. 2002 J. Bone Miner. Res. pmid:11874237
Bolon B et al. Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. 2002 Cell. Mol. Life Sci. pmid:12440777
David JP et al. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. 2002 J. Cell. Sci. pmid:12376563
Jones DH et al. Role of RANKL and RANK in bone loss and arthritis. 2002 Ann. Rheum. Dis. pmid:12379618
Gravallese EM Bone destruction in arthritis. 2002 Ann. Rheum. Dis. pmid:12379632

Table of Content